ウイルス性結膜炎治療薬市場：薬剤クラス別、ウイルスタイプ別、流通チャネル別、地域別

ウイルス性結膜炎治療薬市場は、2025年には3億7,500万米ドルと推定され、2032年には5億3,120万米ドルに達すると予測され、2025～2032年にかけてCAGR5.1％で成長すると予測されます。

ウイルス性結膜炎は、アデノウイルス、単純ヘルペスウイルスなどの様々なウイルスが原因で起こる急性の結膜感染症です。ウイルス性結膜炎は感染性結膜炎の大部分を占め、症例の75％を占めます。ウイルス性結膜炎の特徴としては、充血、血管充血、眼脂、痛み、羞明などが挙げられます。アデノウイルス群によって引き起こされるウイルス性結膜炎は流行性角結膜炎（EKC）と呼ばれます。このアデノウイルス群にはさまざまな血清型があり、咽頭結膜熱や非特異的な濾胞性結膜炎を引き起こすこともあります。American Academy of Ophthalmology：2018に掲載された紙製によると、アデノウイルス性結膜炎は成人集団で最も一般的な眼感染症です。アデノウイルス性結膜炎は、感染の原因となるウイルスがカウンタートップや同様の表面で数週間生存できるため、感染力が非常に強いです。

市場力学

開発企業は、アデノウイルス性結膜炎のより効率的な治療薬法を開発するために臨床検査を実施しており、予測期間中の市場の成長に貢献する可能性があります。例えば、2017年には武田薬品工業の子会社であるShire Plcが、アデノウイルス性結膜炎に罹患している成人と小児の治療薬候補SHP640の安全性と有効性を検証するための臨床検査を開始しました。

市場参入企業は新製品の上市に注力しており、世界市場での地位強化が期待されています。例えば、2018年、Abbvie Inc.の子会社であるAllergan plc.は、新しい一般用（OTC）人工涙液製剤「リフレッシュリペア潤滑点眼液」を発売しました。カルボキシメチルセルロース（CMC）、ヒアルロン酸（HA、非活性成分）、浸透圧保護剤が配合されており、ドライアイなどの結膜炎症状の弊害から目を保護します。

市場参入企業は、流通を強化するために他の企業とパートナーシップを結ぶことで世界的プレゼンスの拡大に関与しており、これがウイルス性結膜炎治療薬市場の成長を促進すると予想されます。例えば、2018年にMundipharma Deutschland GmbH & Co.KG（製薬会社）は、ラテンアメリカ全体で一連の眼科用医薬品のライセンス供与と販売の独占権を取得するため、NTC（イタリアの製薬会社）と商業提携を結ぶことで、ラテンアメリカにおける眼科用医薬品のポートフォリオを拡大した。

本調査の主要特徴

• 本レポートは、世界のウイルス性結膜炎治療薬市場を詳細に分析し、2024年を基準年とした予測期間2025～2032年の市場規模を提供しています。
• 異なるセグメントにわたる潜在的な収益機会を解明し、この市場の魅力的な投資提案マトリクスを説明します。
• また、市場促進要因、抑制要因、機会、新製品の上市や承認、地域による展望、主要企業が採用する競合戦略などに関する重要な考察も提供しています。
• 企業概要、財務実績、製品ポートフォリオ、地理的プレゼンス、流通戦略、主要開発と戦略、将来計画などのパラメータに基づいて、世界のウイルス性結膜炎治療薬市場の主要企業をプロファイルしています。
• 本レポートから洞察により、マーケティング担当者や企業の経営陣は、将来の製品発売、技術向上、市場拡大、マーケティング戦術に関する情報に基づいた意思決定を行うことができます。
• 世界のウイルス性結膜炎治療薬市場レポートは、投資家、サプライヤー、メーカー、流通業者、新規参入者、財務アナリストなど、この産業の様々な利害関係者に対応しています。
• 利害関係者は、ウイルス性結膜炎薬市場分析に使用される様々な戦略マトリックスを通じて、意思決定を容易にすることができます。

目次

第1章 調査目的と前提条件

• 調査目的
• 前提条件
• 略語

第2章 市場展望

• レポートの説明
  • 市場の定義と範囲
• エグゼクティブサマリー

第3章 市場力学、規制、動向分析

• 市場力学
  • 促進要因
  • 抑制要因
  • 市場機会
• 影響分析
• 最近のテスト打ち上げ
• 疫学
• 合併、買収、コラボレーション
• 規制シナリオ
• PEST分析

第4章 世界のウイルス性結膜炎治療薬市場、薬剤クラス別、2020～2032年

• イントロダクション
• 抗生物質
• 人工涙液
• 鼻づまり解消薬
• 抗ヒスタミン薬
• NSAIDs
• 抗ウイルス薬
• その他

第5章 世界のウイルス性結膜炎治療薬市場、ウイルスタイプ別、2020～2032年

• イントロダクション
• アデノウイルス
• エンテロウイルス
• その他（単純ヘルペスウイルス（HSV）など）

第6章 世界のウイルス性結膜炎治療薬市場、流通チャネル別、2020～2032年

• イントロダクション
• 病院薬局
• 小売薬局
• オンライン薬局

第7章 世界のウイルス性結膜炎治療薬市場、地域別、2020～2032年

• イントロダクション
• 北米
  • 米国
  • カナダ
• 欧州
  • 英国
  • ドイツ
  • イタリア
  • フランス
  • スペイン
  • ロシア
  • その他の欧州
• アジア太平洋
  • 中国
  • インド
  • 日本
  • ASEAN諸国
  • オーストラリア
  • 韓国
  • その他のアジア太平洋
• ラテンアメリカ
  • ブラジル
  • メキシコ
  • アルゼンチン
  • その他のラテンアメリカ
• 中東
  • GCC諸国
  • イスラエル
  • その他の中東
• アフリカ
  • 北アフリカ
  • 中央アフリカ
  • 南アフリカ

第8章 競合情勢

• 企業プロファイル
  • AbbVie Inc.
  • Takeda Pharmaceutical Company Limited
  • Bausch Health Companies Inc.
  • Panoptes Pharma Ges.mbH
  • NovaBay Pharmaceuticals, Inc.
  • Nicox, NanoViricides Inc.
  • Novartis International AG
  • Pfizer Inc.
  • Johnson & Johnson
  • GlaxoSmithKline Plc.
  • Santen Pharmaceutical Co.Ltd.
  • Alcon
  • Okogen Inc.

第9章 セクション

• 参考文献
• 調査手法

Viral Conjunctivitis Drugs Market is estimated to be valued at USD 375 Mn in 2025 and is expected to reach USD 531.2 Mn by 2032, growing at a compound annual growth rate (CAGR) of 5.1% from 2025 to 2032.

Viral conjunctivitis is an acute conjunctival infection that is caused due to various viruses such adenovirus, herpes simplex virus etc. Viral conjunctivitis is responsible for majority of infectious conjunctivitis accounting for up to 75% of cases. Characteristics of occular viral conjunctivitis include redness, blood vessel engorgement, ocular discharge, pain, photophobia etc. Viral conjunctivitis that is caused by a group of adenoviruses is called Epidemic Keratoconjunctivitis (EKC). This family of adenoviruses contains different serotypes that can cause pharyngoconjunctival fever and nonspecific follicular conjunctivitis as well. According to the article published in the American Academy of Ophthalmology: 2018, adenoviral conjunctivitis is the most common type of eye infection in adult population. The adenoviral conjunctivitis is highly contagious as the virus causing the infection can survive on a countertop or a similar surface for several weeks.

Market Dynamics

Market players are conducting clinical trials for developing more efficient treatments for adenoviral conjunctivitis, which could contribute to the growth of the market over the forecast period. For instance, in 2017, Shire Plc, subsidiary of Takeda Pharmaceutical Company, initiated clinical trials for testing the safety and efficacy of its drug candidate SHP640 for the treatment of adults and children suffering from adenoviral conjunctivitis.

Market players are focusing on the launch of new products, which is expected to strengthen their position in the global market. For instance, in 2018, Allergan plc., a subsidiary of Abbvie Inc., launched a new over-the-counter (OTC) artificial tear formulation, REFRESH REPAIR Lubricant Eye Drops. It is formulated with carboxymethylcellulose (CMC), hyaluronic acid (HA, an inactive ingredient), and osmoprotectants that protects the eyes from the harmful effects of conjunctivitis symptoms like dry eyes.

Market players are involved in expanding their global presence by entering into partnerships with other companies in order to enhance distribution, this is expected to drive the growth of the viral conjunctivitis drugs market. For instance, in 2018, Mundipharma Deutschland GmbH & Co. KG, a pharmaceutical company, expanded its ophthalmology portfolio in Latin America by entering into a commercial partnership with NTC - an Italian pharmaceutical company, for obtaining exclusive rights to license and distribute a range of ophthalmic medicines across the Latin America region.

Key features of the study

• This report provides an in-depth analysis of global viral conjunctivitis drugs market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period 2025-2032, considering 2024 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players.
• It profiles leading players in the global viral conjunctivitis drugs market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans.
• Key companies covered as a part of this study include AbbVie Inc., Takeda Pharmaceutical Company Limited, Bausch Health Companies Inc., Panoptes Pharma Ges.m.b.H, NovaBay Pharmaceuticals, Inc., Nicox, NanoViricides Inc., Novartis International AG, Pfizer Inc., Johnson & Johnson, GlaxoSmithKline Plc., and Okogen Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics.
• The global viral conjunctivitis drugs market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision making through various strategy matrices used in analyzing the viral conjunctivitis drugs market.

Market Segmentation

• Global Viral Conjunctivitis Drugs Market, By Drug Class
  • Artificial tears
  • Decongestants
  • Anti-histamines
  • NSAIDS
  • Anti-Viral drugs
  • Steroids
  • Antibiotics
• Global Viral Conjunctivitis Drugs Market, By Virus Type
  • Adenovirus
  • Enterovirus
  • Others
• Global Viral Conjunctivitis Drugs Market, By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Global Viral Conjunctivitis Drugs Market, By Region
  • North America
  • By Drug Class
  • Artificial tears
  • Decongestants
  • Anti-histamines
  • NSAIDS
  • Anti-Viral drugs
  • Steroids
  • Antibiotics
  • By Virus Type
  • Adenovirus
  • Enterovirus
  • Others
  • By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • By Country
  • U.S.
  • Canada
  • Latin America
  • By Drug Class
  • Artificial tears
  • Decongestants
  • Anti-histamines
  • NSAIDS
  • Anti-Viral drugs
  • Steroids
  • Antibiotics
  • By Virus Type
  • Adenovirus
  • Enterovirus
  • Others
  • By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • By Country
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
  • By Drug Class
  • Artificial tears
  • Decongestants
  • Anti-histamines
  • NSAIDS
  • Anti-Viral drugs
  • Steroids
  • Antibiotics
  • By Virus Type
  • Adenovirus
  • Enterovirus
  • Others
  • By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • By Country
  • U.K.
  • Germany
  • Italy
  • Spain
  • France
  • Russia
  • Rest of Europe
  • Asia Pacific
  • By Drug Class
  • Artificial tears
  • Decongestants
  • Anti-histamines
  • NSAIDS
  • Anti-Viral drugs
  • Steroids
  • Antibiotics
  • By Virus Type
  • Adenovirus
  • Enterovirus
  • Others
  • By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • By Country
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Middle East
  • By Drug Class
  • Artificial tears
  • Decongestants
  • Anti-histamines
  • NSAIDS
  • Anti-Viral drugs
  • Steroids
  • Antibiotics
  • By Virus Type
  • Adenovirus
  • Enterovirus
  • Others
  • By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • By Country
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
  • By Drug Class
  • Artificial tears
  • Decongestants
  • Anti-histamines
  • NSAIDS
  • Anti-Viral drugs
  • Steroids
  • Antibiotics
  • By Virus Type
  • Adenovirus
  • Enterovirus
  • Others
  • By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • By Country/Region
  • South Africa
  • Central Africa
  • North Africa
• Company Profiles
  • AbbVie Inc.
  • Takeda Pharmaceutical Company Limited
  • Bausch Health Companies Inc.
  • Panoptes Pharma Ges.m.b.H
  • NovaBay Pharmaceuticals, Inc.
  • Nicox
  • NanoViricides Inc.
  • Novartis International AG
  • Pfizer Inc.
  • Johnson & Johnson
  • GlaxoSmithKline Plc.
  • Okogen Inc.

Table of Contents

1. Research Objective and Assumption

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snippet, By Drug Class
  • Market Snippet, By Virus Type
  • Market Snippet, By Distribution Channel
  • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Impact Analysis
• Recent Test Launches
• Epidemiology
• Merger, Acquisition, and Collaborations
• Regulatory Scenario
• Key Developments
• PEST Analysis

4. Global Viral Conjunctivitis Drugs Market, By Drug Class, 2020-2032, (USD Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021-2032
  • Segment Trends
• Antibiotics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Segment Trends
• Artificial tears
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Segment Trends
• Decongestants
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Segment Trends
• Anti-histamines
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Segment Trends
• NSAIDS
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Segment Trends
• Anti-Viral drugs
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Segment Trends
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020 -2032, (USD Mn)
  • Segment Trends

5. Global Viral Conjunctivitis Drugs Market, By Virus Type, 2020 - 2032, (USD Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021-2032
  • Segment Trends
• Adenovirus
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (USD Mn)
  • Segment Trends
• Enterovirus
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (USD Mn)
  • Segment Trends
• Others (Herpes Simplex Virus (HSV), etc.)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (USD Mn)
  • Segment Trends

6. Global Viral Conjunctivitis Drugs Market, By Distribution Channel, 2020 - 2032, (USD Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021-2032
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

7. Global Viral Conjunctivitis Drugs Market, By Region, 2020-2032, (USD Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021-2032
  • Segment Trends
• North America
  • Introduction
  • Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2020-2032, (USD Mn)
  • Market Size and Forecast, Y-o-Y Growth and By Virus Type, 2020-2032, (USD Mn)
  • Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2020-2032, (USD Mn)
  • Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2020-2032, (USD Mn)
    • U.S.
    • Canada
• Europe
  • Introduction
  • Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2020-2032, (USD Mn)
  • Market Size and Forecast, Y-o-Y Growth and By Virus Type, 2020-2032, (USD Mn)
  • Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2020-2032, (USD Mn)
  • Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2020-2032, (USD Mn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2020-2032, (USD Mn)
  • Market Size and Forecast, Y-o-Y Growth and By Virus Type, 2020-2032, (USD Mn)
  • Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2020-2032, (USD Mn)
  • Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2020-2032, (USD Mn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Latin America
  • Introduction
  • Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2020-2032, (USD Mn)
  • Market Size and Forecast, Y-o-Y Growth and By Virus Type, 2020-2032, (USD Mn)
  • Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2020-2032, (USD Mn)
  • Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2020-2032, (USD Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Middle East
  • Introduction
  • Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2020 -2032, (USD Mn)
  • Market Size and Forecast, Y-o-Y Growth and By Virus Type, 2020-2032, (USD Mn)
  • Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2020-2032, (USD Mn)
  • Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2020-2032, (USD Mn)
    • GCC
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2020-2032, (USD Mn)
  • Market Size and Forecast, Y-o-Y Growth and By Virus Type, 2020-2032, (USD Mn)
  • Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2020-2032, (USD Mn)
  • Market Size and Forecast, By Country, Y-o-Y Growth and By Country/ Region, 2020-2032, (USD Mn)
    • North Africa
    • Central Africa
    • South Africa

8. Competitive Landscape

• Company Profiles
  • AbbVie Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Strategies
  • Takeda Pharmaceutical Company Limited
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Strategies
  • Bausch Health Companies Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Strategies
  • Panoptes Pharma Ges.m.b.H
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Strategies
  • NovaBay Pharmaceuticals, Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Strategies
  • Nicox, NanoViricides Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Strategies
  • Novartis International AG
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Strategies
  • Pfizer Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Strategies
  • Johnson & Johnson
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Strategies
  • GlaxoSmithKline Plc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Strategies
  • Santen Pharmaceutical Co.Ltd.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Strategies
  • Alcon
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Strategies
  • Okogen Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Strategies

9. Section

• References
• Research Methodology
• About us and Sales Contact